|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang ZT, Chen ZJ, Jiang GM, Wu YM, Liu T,
Yi YM, Zeng J, Du J and Wang HS: Histone deacetylase inhibitors
suppress mutant p53 transcription via HDAC8/YY1 signals in triple
negative breast cancer cells. Cell Signal. 28:506–515. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng XS, Wang S, Deng A, Liu B, Edgerton
SM, Lind SE, Wahdan-Alaswad R and Thor AD: Metformin targets Stat3
to inhibit cell growth and induce apoptosis in triple-negative
breast cancers. Cell Cycle. 11:367–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shu S, Lin CY, He HH, Witwicki RM,
Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, et
al: Response and resistance to BET bromodomain inhibitors in
triple-negative breast cancer. Nature. 529:413–417. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rincón R, Cristóbal I, Zazo S, Arpí O,
Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, et
al: PP2A inhibition determines poor outcome and doxorubicin
resistance in early breast cancer and its activation shows
promising therapeutic effects. Oncotarget. 6:4299–4314. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsukamoto S, Huang Y, Umeda D, Yamada S,
Yamashita S, Kumazoe M, Kim Y, Murata M, Yamada K and Tachibana H:
67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A)
activation elicits melanoma-specific antitumor activity overcoming
drug resistance. J Biol Chem. 289:32671–32681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren J, Li W, Yan L, Jiao W, Tian S, Li D,
Tang Y, Gu G, Liu H and Xu Z: Expression of CIP2A in renal cell
carcinomas correlates with tumour invasion, metastasis and
patients' survival. Br J Cancer. 105:1905–1911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu CY, Shiau CW, Kuo HY, Huang HP, Chen
MH, Tzeng CH and Chen KF: Cancerous inhibitor of protein
phosphatase 2A determines bortezomib-induced apoptosis in leukemia
cells. Haematologica. 98:729–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiao X, He Z, Cao W, Cai F, Zhang L, Huang
Q, Fan C, Duan C, Wang X, Wang J, et al: Oridonin inhibits
gefitinib-resistant lung cancer cells by suppressing
EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol.
48:2608–2618. 2016.PubMed/NCBI
|
|
13
|
Seshacharyulu P, Pandey P, Datta K and
Batra SK: Phosphatase: PP2A structural importance, regulation and
its aberrant expression in cancer. Cancer Lett. 335:9–18. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schönthal AH: Role of serine/threonine
protein phosphatase 2A in cancer. Cancer Lett. 170:1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lv P, Wang Y, Ma J, Wang Z, Li JL, Hong
CS, Zhuang Z and Zeng YX: Inhibition of protein phosphatase 2A with
a small molecule LB100 radiosensitizes nasopharyngeal carcinoma
xenografts by inducing mitotic catastrophe and blocking DNA damage
repair. Oncotarget. 5:7512–7524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho MK, Park JW, Jang YP, Kim YC and Kim
SG: Potent inhibition of lipopolysaccharide-inducible nitric oxide
synthase expression by dibenzylbutyrolactone lignans through
inhibition of I-kappaBalpha phosphorylation and of p65 nuclear
translocation in macrophages. Int Immunopharmacol. 2:105–116. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yao X, Zhu F, Zhao Z, Liu C, Luo L and Yin
Z: Arctigenin enhances chemosensitivity of cancer cells to
cisplatin through inhibition of the STAT3 signaling pathway. J Cell
Biochem. 112:2837–2849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng T, Cao W, Shen W, Zhang L, Gu X, Guo
Y, Tsai HI, Liu X, Li J, Zhang J, et al: Arctigenin inhibits STAT3
and exhibits anticancer potential in human triple-negative breast
cancer therapy. Oncotarget. 8:329–344. 2017.PubMed/NCBI
|
|
19
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P, et al: Homoharringtonine
induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal
pathway in Gefitinib-resistant lung cancer cells. Sci Rep.
5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang
Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET
oncoprotein is associated with tumor progression and poor prognosis
in human non-small cell lung cancer. Oncotarget. 6:14913–14925.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Dong Y, Zhang B and Cheng YX: Small
compound 6-O-angeloylplenolin induces caspase-dependent apoptosis
in human multiple myeloma cells. Oncol Lett. 6:556–558.
2013.PubMed/NCBI
|
|
23
|
Li S, Feng TT, Guo Y, Yu X, Huang Q, Zhang
L, Tang W and Liu Y: Expression of cancerous inhibitor of protein
phosphatase 2A in human triple negative breast cancer correlates
with tumor survival, invasion and autophagy. Oncol Lett.
12:5370–5376. 2016.PubMed/NCBI
|
|
24
|
Come C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wright HJ, Arulmoli J, Motazedi M, Nelson
LJ, Heinemann FS, Flanagan LA and Razorenova OV: CDCP1 cleavage is
necessary for homodimerization-induced migration of triple-negative
breast cancer. Oncogene. 35:4762–4772. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cristobal I, Rincon R, Manso R, Caramés
C1, Zazo S2, Madoz-Gúrpide J2, Rojo F3 and García-Foncillas J:
Deregulation of the PP2A inhibitor SET shows promising therapeutic
implications and determines poor clinical outcome in patients with
metastatic colorectal cancer. Clin Cancer Res. 21:347–356. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu HC, Hung MH, Chen YL, Chu PY, Wang CY,
Chao TT, Liu CY, Shiau CW and Chen KF: Erlotinib derivative
inhibits hepatocellular carcinoma by targeting CIP2A to reactivate
protein phosphatase 2A. Cell Death Dis. 5:e13592014. View Article : Google Scholar : PubMed/NCBI
|
